文献速递认知障碍与痴呆帕金森病与运动障碍

胆碱酯酶抑制剂治疗阿尔茨海默病和帕金森病精神病性症状:一项Meta分析

Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.
PubMed 文献 · JAMA Neurol · 2023-01-01

该个体参与者数据Meta分析纳入34项随机临床试验,从17项试验获得6649例参与者的个体数据,评估胆碱酯酶抑制剂对阿尔茨海默病、帕金森病及路易体痴呆患者幻觉和妄想的效果。结果显示,在阿尔茨海默病和帕金森病亚组中,胆碱酯酶抑制剂治疗与妄想和幻觉的改善相关,效应量较小。

要点

  • 在阿尔茨海默病亚组,胆碱酯酶抑制剂治疗与妄想改善相关(-0.08;95% CI,-0.14至-0.03;P=0.006)。
  • 在阿尔茨海默病亚组,胆碱酯酶抑制剂治疗与幻觉改善相关(-0.09;95% CI,-0.14至-0.04;P=0.003)。
  • 在帕金森病亚组,胆碱酯酶抑制剂治疗与妄想(-0.14;95% CI,-0.26至-0.01;P=0.04)和幻觉(-0.08;95% CI,-0.13至-0.03;P=0.01)改善相关。

核心结论

  • 该个体参与者数据Meta分析结果提示,胆碱酯酶抑制剂治疗可改善阿尔茨海默病和帕金森病患者的精神病性症状,效应量较小。

研究设计与样本

  • 系统检索PubMed(MEDLINE)、Embase和PsychInfo,无年份限制,最终检索截止日期为2022年4月21日,并从参考文献列表补充合格研究。
  • 纳入标准为安慰剂对照随机临床试验,包含至少1个多奈哌齐、利斯的明或加兰他敏治疗组,患者为阿尔茨海默病、帕金森病或路易体痴呆,应用至少1项包含幻觉和/或妄想的神经精神评估工具,并有英文全文。
  • 共纳入34项合格随机临床试验;从17项试验获得6649例参与者的个体数据(3830例[62.6%]为女性;平均[SD]年龄75.0[8.2]岁),其中阿尔茨海默病12项、帕金森病5项,路易体痴呆无个体参与者数据可用。
  • 采用两阶段Meta分析,使用随机效应模型,遵循PRISMA指南提取数据和评估数据质量与有效性,数据提取由第二位评价者核对。

主要发现

  • 在阿尔茨海默病亚组,胆碱酯酶抑制剂治疗与妄想相关(-0.08;95% CI,-0.14至-0.03;P=0.006)。
  • 在阿尔茨海默病亚组,胆碱酯酶抑制剂治疗与幻觉相关(-0.09;95% CI,-0.14至-0.04;P=0.003)。
  • 在帕金森病亚组,胆碱酯酶抑制剂治疗与妄想相关(-0.14;95% CI,-0.26至-0.01;P=0.04)。
  • 在帕金森病亚组,胆碱酯酶抑制剂治疗与幻觉相关(-0.08;95% CI,-0.13至-0.03;P=0.01)。

关键数值与推荐

  • 主要结局为幻觉和妄想;次要结局包括所有其他个体神经精神子域以及总神经精神评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 路易体痴呆无个体参与者数据可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psychotic symptoms greatly increase the burden of disease for people with neurodegenerative disorders and their caregivers. Cholinesterase inhibitors (ChEIs) may be effective treatment for psychotic symptoms in these disorders. Previous trials only evaluated neuropsychiatric symptoms as a secondary and an overall outcome, potentially blurring the outcomes noted with ChEI use specifically for psychotic symptoms. OBJECTIVE: To quantitatively assess the use of ChEIs for treatment of individual neuropsychiatric symptoms, specifically hallucinations and delusions, in patients with Alzheimer disease (AD), Parkinson disease (PD), and dementia with Lewy bodies (DLB). DATA SOURCES: A systematic search was performed in PubMed (MEDLINE), Embase, and PsychInfo, without year restrictions. Additional eligible studies were retrieved from reference lists. The final search cutoff date was April 21, 2022. STUDY SELECTION: Studies were selected if they presented the results of placebo-controlled randomized clinical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients with AD, PD, or DLB; if they applied at least 1 neuropsychiatric measure including hallucinations and/or delusions; and if a full-text version of the study was available in the English language. Study selection was performed and checked by multiple reviewers. DATA EXTRACTION AND SYNTHESIS: Original research data were requested on eligible studies. A 2-stage meta-analysis was then performed, using random-effects models. Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed for extracting data and assessing the data quality and validity. Data extraction was checked by a second reviewer. MAIN OUTCOMES AND MEASURES: Primary outcomes were hallucinations and delusions; secondary outcomes included all other individual neuropsychiatric subdomains as well as the total neuropsychiatric score. RESULTS: In total, 34 eligible randomized clinical trials were selected. Individual participant data on 6649 individuals (3830 [62.6%] women; mean [SD] age, 75.0 [8.2] years) were obtained from 17 trials (AD: n = 12; PD: n = 5; individual participant data were not available for DLB). An association with ChEI treatment was shown in the AD subgroup for delusions (-0.08; 95% CI, -0.14 to -0.03; P = .006) and hallucinations (-0.09; 95% CI, -0.14 to -0.04; P = .003) and in the PD subgroup for delusions (-0.14; 95% CI, -0.26 to -0.01; P = .04) and hallucinations (-0.08, 95% CI -0.13 to -0.03; P = .01). CONCLUSIONS AND RELEVANCE: The results of this individual participant data meta-analysis suggest that ChEI treatment improves psychotic symptoms in patients with AD and PD with small effect sizes.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. d'Angremont E, Begemann MJH, van Laar T, et al. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. 2023. PMID: 37358841. doi:10.1001/jamaneurol.2023.1835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。